Structure‐kinetic relationship analysis of the therapeutic complement inhibitor compstatin
- 6 August 2009
- journal article
- research article
- Published by Wiley in Journal of Molecular Recognition
- Vol. 22 (6), 495-505
- https://doi.org/10.1002/jmr.972
Abstract
Compstatin is a 13‐residue peptide that inhibits activation of the complement system by binding to the central component C3 and its fragments C3b and C3c. A combination of theoretical and experimental approaches has previously allowed us to develop analogs of the original compstatin peptide with up to 264‐fold higher activity; one of these analogs is now in clinical trials for the treatment of age‐related macular degeneration (AMD). Here we used functional assays, surface plasmon resonance (SPR), and isothermal titration calorimetry (ITC) to assess the effect of modifications at three key residues (Trp‐4, Asp‐6, Ala‐9) on the affinity and activity of compstatin and its analogs, and we correlated our findings to the recently reported co‐crystal structure of compstatin and C3c. The K D values for the panel of tested analogs ranged from 10−6 to 10−8 M. These differences in binding affinity could be attributed mainly to differences in dissociation rather than association rates, with a >4‐fold range in k on values (2–10 × 105 M−1 s−1) and a k off variation of >35‐fold (1–37 × 10−2 s−1) being observed. The stability of the C3b‐compstatin complex seemed to be highly dependent on hydrophobic effects at position 4, and even small changes at position 6 resulted in a loss of complex formation. Induction of a β‐turn shift by an A9P modification resulted in a more favorable entropy but a loss of binding specificity and stability. The results obtained by the three methods utilized here were highly correlated with regard to the activity/affinity of the analogs. Thus, our analyses have identified essential structural features of compstatin and provided important information to support the development of analogs with improved efficacy. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 38 references indexed in Scilit:
- Path-Integral Method for Predicting Relative Binding Affinities of Protein−Ligand ComplexesJournal of the American Chemical Society, 2009
- Age-related macular degenerationThe Lancet, 2008
- Development of a New Pharmacophore Model That Discriminates Active Compstatin AnalogsChemical Biology & Drug Design, 2008
- Complement-targeted therapeuticsNature Biotechnology, 2007
- Structure of Compstatin in Complex with Complement Component C3c Reveals a New Mechanism of Complement InhibitionJournal of Biological Chemistry, 2007
- The Role of Complement in Inflammatory Diseases From Behind the Scenes into the SpotlightThe American Journal of Pathology, 2007
- A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatinBioorganic & Medicinal Chemistry, 2007
- Thermodynamic Studies on the Interaction of the Third Complement Component and Its Inhibitor, CompstatinOnline Journal of Public Health Informatics, 2004
- Inhibitor of complement, Compstatin, prevents polymer‐mediated Mac‐1 up‐regulation of human neutrophils independent of biomaterial type testedJournal of Biomedical Materials Research Part A, 2003
- Solid‐Phase Peptide SynthesisPublished by Wiley ,1969